Summary of Significant Accounting Policies (Tables)

12 Months Ended

Jun. 30, 2018

Summary of Significant Accounting Policies

Schedule of the Company's net sales by medical indication

(In thousands)	Fiscal Year Ended June 30,
Medical Indication	2018		2017			2016
Antibiotic	$	14,509	$	16,748		$	14,558
Anti-Psychosis	59,557		58,625			5,462
Cardiovascular	64,011		50,628			53,541
Central Nervous System	31,789		39,451			36,291
Gallstone	20,280		48,600			67,348
Gastrointestinal	60,294		71,887			52,699
Glaucoma	6,540		18,763			25,336
Migraine	54,015		29,014			21,776
Muscle Relaxant	13,496		13,636			5,403
Pain Management	23,036		26,135			29,804
Respiratory	7,891		10,516			9,982
Thyroid Deficiency	245,929		174,005			162,411
Urinary	8,661		14,695			17,398
Other	54,720		47,196			42,039
Contract manufacturing revenue	19,835		17,442			22,043
Net sales	684,563		637,341			566,091
Settlement agreement	—		(4,000		)	(23,598		)
Total net sales	$	684,563	$	633,341		$	542,493

Summary of products which accounted for at least 10% of total net sales

	June 30, 2018		June 30, 2017		June 30, 2016
Product 1	36	%	27	%	30	%
Product 2	3	%	8	%	12	%

Summary of customers which accounted for at least 10% of total net sales

	June 30, 2018		June 30, 2017		June 30, 2016
Customer A	29	%	28	%	25	%
Customer B	17	%	21	%	16	%